MedTrace Logo

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

NCT05932641 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-12-27

No results posted yet for this study

Summary

AZD3152 is being evaluated for administration to prevent COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD3152 as well as relevant data on the PK, PD (as the neutralising responses against SARS-CoV-2) profile and the generation of ADA to AZD3152.

Conditions

  • COVID-19, SARS-CoV-2

Interventions

BIOLOGICAL

AZD3152 (Cohort 1)

Single dose of AZD3152 300 mg IM on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 1)

Single dose of Placebo IM on Visit 2 Day 1

BIOLOGICAL

AZD3152 (Cohort 2)

Single dose of AZD3152 600 mg IM on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 2)

Single dose of Placebo IM on Visit 2 Day 1

BIOLOGICAL

AZD3152 (Cohort 3)

Single dose of AZD3152 1200 mg IV on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 3)

Single dose of Placebo IM on Visit 2 Day 1

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2024-12-05
Completion
2024-12-05
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05932641 on ClinicalTrials.gov